Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2014 Sep 9;111(6):1132-8. doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.

Author information

  • 11] The Oncology Institute the Chaim Sheba Medical Center, Tel Hashomer, Israel [2] The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 21] Department of Surgery, University Health Network, Toronto, ON, Canada [2] Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
  • 31] Department of Oncology, Rambam Health Care Campus, University of Haifa, Haifa, Israel [2] Technion, Faculty of Medicine, Haifa, Israel.
  • 41] Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel [2] Institute of Human Genetics, Rambam Health Care Campus, University of Haifa, Haifa, Israel.
  • 51] Technion, Faculty of Medicine, Haifa, Israel [2] Institute of Human Genetics, Rambam Health Care Campus, University of Haifa, Haifa, Israel.
  • 6Department of Surgery, University Health Network, Toronto, ON, Canada.
  • 71] The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] The Susanne Levy Gertner Oncogenetics Unit Chaim Sheba Medical Center, Tel Hashomer, Israel.

Abstract

BACKGROUND:

The BRCA1/2 proteins are involved in regulation of cellular proliferation by DNA damage repair via homologous recombination. Therefore, BRCA1/2 mutation carriers with pancreatic cancer may have distinct biologic outcomes.

METHODS:

Patients with BRCA1/2-associated pancreatic ductal adenocarcinoma (PDAC) diagnosed between January 1994 and December 2012 were identified from databases at three participating institutions. Clinical data were collected. Disease-free survival and overall survival (OS) were analysed.

RESULTS:

Overall, 71 patients with PDAC and BRCA1 (n=21), BRCA2 (n=49) or both (n=1) mutations were identified. Mean age at diagnosis was 60.3 years (range 33-83), 81.7% (n=58) had any family history of malignancy; 30% (n=21) underwent primary resection. Out of 71 participants, 12 received experimental therapy; one patient had missing data, these 13 cases were excluded from OS analysis. Median OS for 58 patients was 14 months (95% CI 10-23 months). Median OS for patients with stage 1/2 disease has not been reached with 52% still alive at 60 months. Median OS for stage 3/4 was 12 months (95% CI 6-15). Superior OS was observed for patients with stage 3/4 treated with platinum vs those treated with non-platinum chemotherapies (22 vs 9 months; P=0.039).

CONCLUSION:

Superior OS was observed for advanced-disease BRCA-associated PDAC with platinum exposure.

PMID:
25072261
PMCID:
PMC4453851
DOI:
10.1038/bjc.2014.418
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center